BiotechTube
Home/Pipeline/Tanabe-Veneno Program

Tanabe-Veneno Program

Undisclosed

ExploratoryActive

Key Facts

Indication
Undisclosed
Phase
Exploratory
Status
Active
Company
Alpha Fusion

About Alpha Fusion

A Japanese biotech developing targeted alpha therapies using Astatine-211 for precise cancer treatment with minimal side effects.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed Drugs

DrugCompanyPhase
Preclinical ISAC 1Bolt BiotherapeuticsPreclinical
Preclinical ISAC 2Bolt BiotherapeuticsPreclinical
ART12.11Artelo BiosciencesPreclinical
Novel VaccinesMSDDevelopment
SLS-009Seelos TherapeuticsDiscovery
Technosphere Platform (New Formulations)MannKindDiscovery/Preclinical
Measovir®-based Prophylactic Vaccine (with Unither)OncovitaResearch/Pre-clinical
Internal sdAb Discovery ProgramNanoTag BiotechnologiesDiscovery
NB-701Nerai BiosciencesDiscovery
Undisclosed Therapeutic Program(s)Bright CellClinical Trial (Phase unspecified)
Biosimilars PipelineIntelligent TherapeuticsPre-clinical/Development
Proprietary Therapeutic PipelineExcelsior SciencesDiscovery